BAYER AG

The Agriculture Biotechnology Market is projected to reach USD 158.0 billion by 2024 and USD 287.0 billion by 2033, with a CAGR of 6.9%. The US market is expected to reach USD 50.1 billion in 2024 at a CAGR of 6.5%. Key drivers include advancements in gene editing, sustainable farming practices, and rising food demand. Challenges include regulatory hurdles, public skepticism, and high development costs.

Agricultural biotechnology uses scientific methods to transform organisms for agricultural production, integrating fields like genetics and molecular biology to develop crops and livestock with desired traits. The US market offers growth through gene editing, crop resilience, and sustainable farming, driven by strong R&D and partnerships. Key trends include CRISPR, sustainable bio-stimulants, synthetic biology, and digital agriculture integration. Major players like BASF SE and Bayer AG focus on strategic partnerships and sustainable solutions. Challenges include regulatory hurdles, public skepticism, and high R&D costs. Opportunities lie in climate-resilient crops, bio-based products, emerging markets, and precision agriculture.

Linear ablation combined with ethanol infusion via the vein of Marshall (EIVOM) significantly improves freedom from atrial arrhythmia recurrence without antiarrhythmic drugs (70.7% vs 61.5%; hazard ratio, 0.73) in patients with persistent atrial fibrillation (AF) undergoing first-time ablation, according to a randomized clinical trial involving 498 patients.

The atopic dermatitis market is projected to grow from $7.51 billion in 2023 to $15.27 billion by 2028, driven by advancements in biologic therapies, personalized medicine, and product innovations. Key players include Sanofi SA, Regeneron Pharmaceuticals Inc., and Novartis International AG.

The ICA Foundation, formed by Population Council and Schering (now Bayer), has donated nearly 250,000 hormonal IUDs to 47 countries since 2005, significantly expanding access to effective contraception and treatment for heavy menstrual bleeding, iron-deficiency anemia, and endometriosis pain in low- and middle-income countries.

The Agricultural Biotechnology Market is projected to grow from USD 116 Billion in 2023 to USD 227.77 Billion by 2031, at a CAGR of 8.8%. This growth is driven by changing consumer preferences, technological advancements, and sustainability emphasis. The market is segmented by technology, organism, application, and region, with key players including Marrone Bio Innovations, ADAMA Ltd., and Bayer AG.

Trogenix, a spinout from the University of Edinburgh, unveils its precision viral immunotherapy platform, Odysseus, targeting aggressive cancers. The company, backed by 4BIO Capital and other investors, aims to transform cancer treatment from chronic management to potentially curative one-time treatments. Trogenix's Synthetic Super-Enhancer technology enables selective targeting of cancer cells, activating the immune system while leaving healthy cells untouched. The lead programme targets glioblastoma, with Phase 1/2 trials planned for 2025.

Astellas Korea's CEO, Kim Junil, highlights Padsep, an innovative bladder cancer treatment doubling survival periods, and the swift introduction of new biologics for gastric cancer, emphasizing the company's commitment to patient benefits and innovative drug accessibility.

BRAIN-AF trial finds rivaroxaban does not reduce neurocognitive decline, stroke, or TIA risk in adults under 65 with atrial fibrillation, challenging the use of oral anticoagulation in younger, lower-risk patients.

Tirzepatide significantly reduced cardiovascular mortality and worsening heart failure events by nearly 40% in patients with obesity and heart failure with preserved ejection fraction (HFpEF), according to the SUMMIT trial. The treatment notably decreased hospitalizations and urgent HF events, improved health status, exercise tolerance, and reduced body weight and systemic inflammation.